aid: alphabiopharma
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/alphabiopharma.png
name: Alpha Biopharma
description: 'Alpha Biopharma is a clinical-stage biopharmaceutical company founded in 2017 and headquartered
  in Shanghai, China, with an additional office in Beijing. The company focuses on the clinical development
  and commercialization of global innovative drugs across oncology and immunotherapy, spanning medical
  affairs, clinical operations, regulatory affairs and commercialization. Its lead product is Zorifertinib
  (formerly AZD-3759, marketed as Zorifer), a next-generation EGFR TKI designed for EGFR mutation positive
  advanced NSCLC patients with central nervous system metastases, which received NMPA approval in November
  2024 as the first EGFR-TKI indicated for lung cancer with brain metastases. Alpha Biopharma also partners
  with Wugen Inc. on universal off-the-shelf memory NK and CAR-T cell therapies. The company raised a
  Series A led by Qiming Venture Partners. Alpha Biopharma publishes a corporate marketing website only
  and operates no public API, developer portal, or software platform.'
url: https://raw.githubusercontent.com/api-evangelist/alphabiopharma/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Oncology
- Immunotherapy
- Clinical Development
- Life Sciences
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/alphabiopharma-domain-security.yml
- type: Website
  url: https://www.alphabiopharma.com/en/
- type: About
  url: https://www.alphabiopharma.com/en/company/1.html
- type: Blog
  url: https://www.alphabiopharma.com/en/news/15.html
- type: Press
  url: https://www.alphabiopharma.com/en/news/36.html
- type: Pipeline
  url: https://www.alphabiopharma.com/en/productline/30.html
- type: Contact
  url: https://www.alphabiopharma.com/en/contact/23.html
- type: Careers
  url: https://www.alphabiopharma.com/en/vocation/20.html
- type: Investors
  url: https://www.alphabiopharma.com/en/investment/27.html
- type: Publications
  url: https://www.alphabiopharma.com/en/innovation/38.html
- type: Research
  url: https://www.alphabiopharma.com/en/development/31.html
- type: Products
  url: https://www.alphabiopharma.com/en/medicine1/32.html
- type: TherapeuticAreas
  url: https://www.alphabiopharma.com/en/ta/7.html
- type: CorporateSocialResponsibility
  url: https://www.alphabiopharma.com/en/society/29.html
- type: WellKnown
  url: well-known/alphabiopharma-well-known.yml
- type: Packages
  url: packages/alphabiopharma-packages.yml
- type: LLMsTxt
  url: llms/alphabiopharma-llms.txt
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1